At a glance
ClinicalIndex Comparison Record- ✓Pathologically confirmed esophageal squamous cell carcinoma
- ✓No prior systemic or local treatment for esophageal cancer
- ✓Age 18-75 years
- ✓ECOG performance status 0-1
- ✕Unresectable tumors or unresectable surgical contraindications
- ✕Supraclavicular lymph node metastasis
- ✕Poor nutritional status, BMI <18.5 kg/m²
- ✕Known allergy to study drug components
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Neoadjuvant Chemoradiotherapy Alone for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma (NICE 2): a Multi-center, Randomized Phase II Trial
In Brief
A Phase 3 clinical trial evaluating Camrelizumab and radiotherapy for Resectable Esophageal Squamous Cell Carcinoma. Currently recruiting, targeting 426 participants across 5 sites.
Detailed Summary
The purpose of this study is to explore the effectiveness and safety of neoadjuvant immune combined chemotherapy or radiochemotherapy compared with traditional neoadjuvant radiochemotherapy in patients with locally advanced Esophageal Squamous Cell Carcinoma.
Study Details
Timeline
Interventions
The study perform preoperative neoadjuvant therapy, surgery and postoperative adjuvant therapy on subjects. Preoperative neoadjuvant therapy includes 3 groups: iCamrelizumab combined with neoadjuvant chemotherapy; Camrelizumab combined with neoadjuvant radiochemotherapy, and neoadjuvant radiochemotherapy.
The study perform preoperative neoadjuvant therapy, surgery and postoperative adjuvant therapy on subjects. Preoperative neoadjuvant therapy includes 3 groups: iCamrelizumab combined with neoadjuvant chemotherapy; Camrelizumab combined with neoadjuvant radiochemotherapy, and neoadjuvant radiochemotherapy.